|
BEVS Products | Influenza H5N1 HA
Note: Produced following emergency request of CDC responding to avian (H5N1) influenza
Description
- Recombinant influenza hemagglutinin (HA) gene product
- Avian influenza H5N1 strain
- Produced using baculovirus vectors in insect cells
- Full length authentic H5 HA protein is produced.
- Forms trimers (trypsin resistant).
- 95% pure
- 1700 doses delivered to NIH.
Functional Activity and Use
- Reactive against H5 HA specific antibodies.
- Positive in hemagglutination assay.
- Induces anti-H5 HA antibodies in experimental animals
Contact Corporate Development, for more information.
Biotech is Hero of
Flu Crisis
ABCNEWS Feb. 5, 1998
1997-1998 timeline
Dec 7 Urgent call from NIH
Dec 8 PSC begins rHA H5 vaccine development
Jan 20 USDA reports 100% protection in chickens
Feb 3 Delivered >1,700 doses rHA "Bird flu" vaccine to NIH
May Phase I sera analysis
|
|
H5 Vaccine
|
|
|
|
|
|
